secwatch.observer — SEC 8-K summary
======================================

Issuer:     Adicet Bio, Inc. (ACET)
CIK:        0001720580
Form:       8-K
Filed at:   2024-09-30T23:59:59+00:00
Accession:  0000950170-24-110166
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adicet opens Phase 1 enrollment for ADI-001 in autoimmune diseases; preliminary data expected H1 2025
--------------------------------------------------------------------------------

- Phase 1 trial now enrolling lupus nephritis (LN) patients; SLE, SSc, AAV enrollment to open Q4 2024.
- FDA granted Fast Track Designation for ADI-001 in relapsed/refractory class III/IV LN.
- Plan to report preliminary clinical data in LN, SLE, SSc, and AAV by first half of 2025.
- Trial has three arms: LN/SLE, SSc, AAV; single dose of ADI-001 with 28-day DLT window and 24-month follow-up.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1720580/000095017024110166/0000950170-24-110166-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1720580/000095017024110166/acet-20240930.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-110166

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer